Zura Bio Ltd (ZURA)

$4.50 +0.19 (4.41%)
Market Cap 292.60M
Revenue (ttm) 0.00
Net Income (ttm) -45.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 179,900
Avg Vol 492,618
Day's Range N/A - N/A
Shares Out 65.02M
Stochastic %K 89%
Beta 0.24
Analysts Strong Sell
Price Target $15.60

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that ne...

Industry: Biotechnology
Sector: Healthcare
Phone: 702 825 9872
Website: zurabio.com
Address:
1489 W. Warm Springs Road, Suite 110, Henderson, United States
FullPorrtDipz
FullPorrtDipz Dec. 23 at 7:36 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Hope for runs on $MLEC $NUKK $OPGN $ZURA to C
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 18 at 12:28 PM
$ZURA Share Price: $4.28 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.84 – $2.28 Target Zone: $3.29 – $4.03 Potential Upside: 69% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
octavia8
octavia8 Dec. 17 at 11:43 PM
$ZURA how high is this realistically going? short term
0 · Reply
Bookshelf1974
Bookshelf1974 Dec. 16 at 7:25 AM
$ZURA 8+ coming, ready to eat.
0 · Reply
Breck100
Breck100 Dec. 12 at 3:21 PM
$ZURA Clear Street analyst Kaveri Pohlman maintained a Buy rating on Zura Bio yesterday and set a price target of $18.00. The company’s shares closed yesterday at $3.72.
0 · Reply
StockConsultant
StockConsultant Nov. 26 at 1:00 PM
$ZURA Zura Bio stock watch, pullback to 3.76 support area with high trade quality at https://stockconsultant.com/?ZURA
0 · Reply
Trizzie0805
Trizzie0805 Nov. 16 at 5:26 PM
Some long term swings! Charts setting up and prime in the weekly chart. Swinging $ZURA acending triangle forming key break out above $4.68 Swinging $RIVN will buy any dip closer to $13 range, looking for the reversal. Swinging $INVE too! Great reversals!
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 8:55 PM
Chardan Capital has updated their rating for Zura Bio ( $ZURA ) to Buy with a price target of 10.
0 · Reply
d_risk
d_risk Nov. 13 at 1:30 PM
$ZURA - Zura Bio Limited Class A Ordinary Shares - 10Q - Updated Risk Factors Zura flags heightened regulatory disruption risks from agency shutdowns, new uncertainties in clinical trial outcomes, intensifying competition, potential adverse impacts from healthcare reforms, stricter data privacy compliance challenges, and dependence on attracting and retaining key personnel. #Biotechnology #DataPrivacy #HealthcareReform #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/ZURA/10-Q/2025-11-13
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 11:12 AM
Clear Street updates rating for Zura Bio ( $ZURA ) to Buy, target set at 18.
0 · Reply
Latest News on ZURA
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Nov 13, 2025, 6:30 AM EST - 6 weeks ago

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 20, 2025, 6:30 AM EDT - 4 months ago

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Aug 14, 2025, 8:15 AM EDT - 4 months ago

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 17, 2025, 4:30 PM EDT - 5 months ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Announces Chief Financial Officer Transition

Jul 1, 2025, 6:30 AM EDT - 6 months ago

Zura Bio Announces Chief Financial Officer Transition

Zura Bio to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 6:30 AM EDT - 7 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025, 6:30 AM EDT - 7 months ago

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 8, 2025, 6:30 AM EDT - 8 months ago

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Mar 25, 2025, 6:30 AM EDT - 9 months ago

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Feb 24, 2025, 6:30 AM EST - 10 months ago

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Dec 23, 2024, 6:30 AM EST - 1 year ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 14, 2024, 4:30 PM EST - 1 year ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 7, 2024, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

Sep 3, 2024, 6:00 AM EDT - 1 year ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Zura Bio to Present at Three Upcoming Investor Conferences in September

Sep 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 9:21 AM EDT - 1 year ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jul 12, 2024, 6:10 AM EDT - 1 year ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 6, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Jun 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Zura Bio Announces Participation in June Investor Conferences

May 29, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Participation in June Investor Conferences

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 18, 2024, 9:22 AM EDT - 1 year ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Zura Bio Announces Robert Lisicki as CEO and Director

Apr 8, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Robert Lisicki as CEO and Director

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 28, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Zura Bio Announces Participation at March Conferences

Mar 4, 2024, 6:00 AM EST - 1 year ago

Zura Bio Announces Participation at March Conferences

Zura Bio Announces Participation at February Investor Conferences

Feb 2, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at February Investor Conferences

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 8, 2024, 6:00 AM EST - 2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Jan 3, 2024, 6:00 AM EST - 2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Dec 4, 2023, 6:00 AM EST - 2 years ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 14, 2023, 6:00 AM EST - 2 years ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 13, 2023, 6:30 AM EST - 2 years ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Sep 12, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 6:30 AM EDT - 2 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Jun 6, 2023, 4:00 AM EDT - 2 years ago

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Apr 27, 2023, 7:39 AM EDT - 2 years ago

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Zura Bio Announces Appointment of Chief Scientific Officer

Apr 14, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Announces Appointment of Chief Scientific Officer

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Mar 21, 2023, 6:13 AM EDT - 3 years ago

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

Mar 16, 2023, 4:17 PM EDT - 3 years ago

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

FullPorrtDipz
FullPorrtDipz Dec. 23 at 7:36 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Hope for runs on $MLEC $NUKK $OPGN $ZURA to C
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 18 at 12:28 PM
$ZURA Share Price: $4.28 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.84 – $2.28 Target Zone: $3.29 – $4.03 Potential Upside: 69% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
octavia8
octavia8 Dec. 17 at 11:43 PM
$ZURA how high is this realistically going? short term
0 · Reply
Bookshelf1974
Bookshelf1974 Dec. 16 at 7:25 AM
$ZURA 8+ coming, ready to eat.
0 · Reply
Breck100
Breck100 Dec. 12 at 3:21 PM
$ZURA Clear Street analyst Kaveri Pohlman maintained a Buy rating on Zura Bio yesterday and set a price target of $18.00. The company’s shares closed yesterday at $3.72.
0 · Reply
StockConsultant
StockConsultant Nov. 26 at 1:00 PM
$ZURA Zura Bio stock watch, pullback to 3.76 support area with high trade quality at https://stockconsultant.com/?ZURA
0 · Reply
Trizzie0805
Trizzie0805 Nov. 16 at 5:26 PM
Some long term swings! Charts setting up and prime in the weekly chart. Swinging $ZURA acending triangle forming key break out above $4.68 Swinging $RIVN will buy any dip closer to $13 range, looking for the reversal. Swinging $INVE too! Great reversals!
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 8:55 PM
Chardan Capital has updated their rating for Zura Bio ( $ZURA ) to Buy with a price target of 10.
0 · Reply
d_risk
d_risk Nov. 13 at 1:30 PM
$ZURA - Zura Bio Limited Class A Ordinary Shares - 10Q - Updated Risk Factors Zura flags heightened regulatory disruption risks from agency shutdowns, new uncertainties in clinical trial outcomes, intensifying competition, potential adverse impacts from healthcare reforms, stricter data privacy compliance challenges, and dependence on attracting and retaining key personnel. #Biotechnology #DataPrivacy #HealthcareReform #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/ZURA/10-Q/2025-11-13
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 11:12 AM
Clear Street updates rating for Zura Bio ( $ZURA ) to Buy, target set at 18.
0 · Reply
SadyK189
SadyK189 Nov. 12 at 2:29 AM
Top Stocks to watch tomorrow 2 / 2: $RIVN $LUCY $IRWD $ZURA $XBIT RIVN: Looking good on daily chart. 16.10 - 16.60 is acting as key support zone. Next key level to test is 19.60 - 20.10. Overall it has long term potential of 24+ ZURA: Good close of daily candle. Key support at 3.4 - 3.8. Next key level to test is 4.95 - 5.30. Currently at 4.41. IRWD is trending nicely on daily chart. 2.15 - 2.35 is acting as key support zone. Next key level to test is 3.35 - 3.55. Currently at 2.95 LUCY: Good close of 4hours candle. Key support at 1.55 - 1.70. Next key level to test is 2.6 - 2.9. Currently at 2.17 XBIT tried to clear stiff resistance of 3.3 - 3.6 zone today but got rejected. Currently at 2.83. It may test this zone again.
0 · Reply
Breck100
Breck100 Nov. 11 at 12:15 PM
$ZURA earnings today?
1 · Reply
Hollandaise56
Hollandaise56 Nov. 4 at 9:10 PM
$ZURA what's happening here...
0 · Reply
deniz100
deniz100 Oct. 27 at 11:25 PM
$ZURA Tommorows runner. 100% move expected!
1 · Reply
djotc
djotc Oct. 27 at 10:54 PM
$ZURA why are so many ppl high on this stock? Analysts calling for $26 pt and stockinvest calling for $11 in the next 90 days. Im in!
0 · Reply
invinc1ble
invinc1ble Oct. 25 at 3:26 PM
$ZURA sleeper. Watch it
0 · Reply
octavia8
octavia8 Oct. 14 at 2:00 PM
$ZURA v shaped recovery??
0 · Reply
jerry_berlin
jerry_berlin Oct. 13 at 3:53 PM
$ZURA why is it going down?
2 · Reply
TraderJay85
TraderJay85 Oct. 10 at 5:34 PM
$ZURA Big win! 🔥 🔥 Went to 4.58. Got in early. We had over 10 poppers so far today. If you are not hitting at least 3 runners a day, then you aint doin something right. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 10 at 1:01 PM
$ZURA
1 · Reply
kkbb
kkbb Oct. 10 at 12:32 PM
$ZURA https://investors.zurabio.com/node/9026/html Zura Bio’s CEO, Robert Lisicki, is taking a medical leave of absence effective October 10, 2025. The company’s COO and Chief Legal Officer, Kim Davis, has been appointed interim CEO while continuing her current roles.
0 · Reply